KS Biomedix licenses TransMID brain cancer product...[Expert Rev Anticancer Ther. 2002]

SearchDatabase nameforSearch term

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

KS Biomedix licenses TransMID brain cancer product to Nycomed in European collaboration.

[No authors listed]

PMID: 12382509 [PubMed - indexed for MEDLINE]

ReviewTechnology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine.
Curr Opin Mol Ther. 2005 Oct; 7(5):483-92.

[Curr Opin Mol Ther. 2005]
Clinical trials referral resource. Multicenter phase I and II trials in adults with high-grade gliomas.
Oncology (Williston Park). 1999 Apr; 13(4):532-3, 537.

[Oncology (Williston Park). 1999]
The closure of Sugen.
Nat Biotechnol. 2003 Sep; 21(9):969.

[Nat Biotechnol. 2003]
European collaboration in trials of new agents for children with cancer.
Eur J Cancer. 2004 Aug; 40(12):1886-92.

[Eur J Cancer. 2004]
ReviewAdvances in molecular therapies in patients with brain tumors.
Cancer Control. 2003 Mar-Apr; 10(2):125-37.

[Cancer Control. 2003]
» See reviews... | » See all...

Your browsing activity is empty.

Activity recording is turned off.

Display Show